May 12, 2021
- Strengthened balance sheet with the completion of a successful IPO - Purchased, built, and activated BioHive-1, reportedly the 58th most powerful supercomputer in the world, to accelerate our drug discovery process - Continued development of internal pipeline and partnership programs remain on
Apr 21, 2021
SALT LAKE CITY, April 21, 2021 / PRNewswire / -- Recursion Pharmaceuticals, Inc. ("Recursion" or "we")  announced the closing on April 20, 2021 of its initial public offering of 27,878,787 shares of its Class A common stock, which includes the exercise in full of the underwriters' option to
Apr 16, 2021
SALT LAKE CITY, April 16, 2021 / PRNewswire / -- Recursion Pharmaceuticals, Inc. ("Recursion" or "we") today announced the pricing of its initial public offering of its Class A common stock at a price to the public of $18.00 per share. Recursion is offering 24,242,424 shares of its Class A common
Mar 01, 2021
Former Goldman Sachs executive to serve as Chairman of Recursion's Board, effective immediately SALT LAKE CITY, March 1, 2021 / PRNewswire / --  Recursion , a digital biology company industrializing drug discovery, today announced the appointment of R. Martin Chavez as Chairman of its Board of
Feb 18, 2021
Former VP & Assistant General Counsel at Pfizer to join Recursion's executive team SALT LAKE CITY, Feb. 18, 2021 / PRNewswire / --  Recursion , a biotechnology company scaling more like a technology company, today announced the appointment of Louisa Daniels, J.D., MBA as its Chief Legal Officer and
Displaying 61 - 70 of 85